HHS calls for review of Medicare Part B premium hike following Aduhelm price cut

HHS Secretary Xavier Becerra is ordering CMS to review its 2022 Medicare Part B premiums following the announcement that Biogen would be slashing the price of its Alzheimer's disease drug in half, according to a Jan. 10 news release. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive